Alteplase

Generic Name
Alteplase
Brand Names
Activase, Cathflo, Cathflo Activase
Drug Type
Biotech
Chemical Formula
-
CAS Number
105857-23-6
Unique Ingredient Identifier
1RXS4UE564
Background

Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin. Alteplase is a purified gl...

Indication

Alteplase is indicated for the treatment of acute ischemic stroke (AIS) and for use in acute myocardial infarction (AMI) for the reduction of mortality and incidence of heart failure. Alteplase is also indicated for the lysis of acute massive pulmonary embolism, defined as acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segments, and...

Associated Conditions
Acute Ischemic Stroke, Cardiac mortality, Heart Failure, Pulmonary Embolism Acute Massive, Central venous access device thrombosis
Associated Therapies
-
Clinical Trials
Related News

Dual IntraVenous Thrombolysis Approach (DIVA) in Patients With Medium-vessel-occlusion Strokes: a Retrospective Study

First Posted Date
2023-04-12
Last Posted Date
2023-11-07
Lead Sponsor
Centre Hospitalier Sud Francilien
Target Recruit Count
294
Registration Number
NCT05809921
Locations
🇫🇷

Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France

Trial of Reduced Alteplase Dose for Parapneumonic Effusion (TRAPPE)

Phase 2
Not yet recruiting
Conditions
Pleural Infection
Interventions
Drug: Tissue Plasminogen Activator
First Posted Date
2023-03-13
Last Posted Date
2024-08-20
Lead Sponsor
Chinese University of Hong Kong
Target Recruit Count
30
Registration Number
NCT05766124
Locations
🇭🇰

Chinese University of Hong Kong, Hong Kong, Hong Kong

🇭🇰

Prince of Wales Hospital, Hong Kong, Hong Kong

Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-Ⅲ）

Phase 3
Recruiting
Conditions
Acute Ischemic Stroke
Interventions
Drug: Alteplase
Drug: Tenecteplase
First Posted Date
2023-02-27
Last Posted Date
2023-02-27
Lead Sponsor
Beijing Tiantan Hospital
Target Recruit Count
1630
Registration Number
NCT05745259
Locations
🇨🇳

Xuanwu Hospital Capital Medical University, Beijing, Beijing, China

🇨🇳

Xuancheng People's Hospital, Xuancheng, Anhui, China

🇨🇳

Beijing Tiantan Hospital, Capital Medical University Beijing, Beijing, Beijing, China

and more 60 locations

Application of tPA in Suprachoroidal and Subretinal Hemorrhage

Not Applicable
Recruiting
Conditions
Ocular Trauma
Interventions
Drug: Tissue Plasminogen Activator
First Posted Date
2023-02-21
Last Posted Date
2023-02-21
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
20
Registration Number
NCT05736757
Locations
🇨🇳

Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Intravenous Tirofiban Versus Alteplase Before Mechanical Thrombectomy in Stroke

Phase 2
Recruiting
Conditions
Stroke, Acute Ischemic
Interventions
Drug: Tirofiban
Drug: Alteplase
First Posted Date
2023-02-15
Last Posted Date
2024-01-03
Lead Sponsor
Xinqiao Hospital of Chongqing
Target Recruit Count
800
Registration Number
NCT05728333
Locations
🇨🇳

Hangzhou First People's Hospital, Hangzhou, Zhejiang, China

rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)

Phase 3
Completed
Conditions
Acute Ischemic Stroke
Interventions
Drug: rhPro-UK
Drug: rt-PA
First Posted Date
2023-01-26
Last Posted Date
2024-07-26
Lead Sponsor
Tasly Biopharmaceuticals Co., Ltd.
Target Recruit Count
1552
Registration Number
NCT05700591
Locations
🇨🇳

Huizhou First Hospital, Guangdong, Guangdong, China

🇨🇳

Tengzhou Central People's Hospital, Dezhou, Shandong, China

🇨🇳

Shengli Oilfield Central Hospital, Dongying, Shandong, China

and more 69 locations

Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure

First Posted Date
2022-09-15
Last Posted Date
2024-04-17
Lead Sponsor
South West Sydney Local Health District
Target Recruit Count
70
Registration Number
NCT05540834
Locations
🇦🇺

Intensive Care Unit, Liverpool Hospital, South Western Sydney Local Health District, Liverpool, New South Wales, Australia

Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas

First Posted Date
2022-08-08
Last Posted Date
2024-03-28
Lead Sponsor
Hamilton Health Sciences Corporation
Target Recruit Count
40
Registration Number
NCT05491356
Locations
🇨🇦

Hamilton General Hospital, Hamilton, Ontario, Canada

Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients

Completed
Conditions
Stroke
Interventions
Drug: rt-PA
First Posted Date
2022-06-02
Last Posted Date
2024-10-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
3058
Registration Number
NCT05401149
Locations
🇨🇳

Boehringer Ingelheim (China) Investment Co., ltd., Shanghai, China

1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients

Completed
Conditions
Stroke
Interventions
Drug: rt-PA
First Posted Date
2022-05-27
Last Posted Date
2024-10-16
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
12551
Registration Number
NCT05395338
Locations
🇨🇳

Boehringer Ingelheim (China) Investment Co., ltd., Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy